A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy

Multicenter Study for the Evaluation of Efficacy and Safety of NeoRecormon® Therapy Administered as 30000 IU Subcutaneously in Anemic Patients With Breast Cancer Treated With Chemotherapy

This study will evaluate the efficacy and safety of subcutaneous (SC) epoetin beta in anemic participants with breast cancer undergoing chemotherapy.

Inclusion Criteria:

• Adult female participants with histological diagnosis of breast cancer
• Any type of chemotherapy planned for greater than or equal to (>/=) 9 weeks
• Hemoglobin level less than (<) 11 grams per deciliter (g/dL)
• Participants able to receive iron supplement, if necessary

Exclusion Criteria:

• Known or suspected contraindications to epoetin beta
• Pregnancy or lactation period
• Diagnosis of anemia only due to iron-deficiency
• Diagnosis of thalasemic syndromes
• Epilepsy and/or cerebral metastasis
• Blood transfusion or treatment with any erythropoietic factor within 4 weeks before study start